Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

R J Motzer

Showing results (81-90 of 155) with videos related to

Pageof 16
Sort By:
Investigational New Drugs|February 1, 1993
A phase II trial of deoxyspergualin in recurrent squamous cell head and neck cancerD G Pfister, D Bajorin, R J Motzer, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 2, 1998
Phase I trial of subcutaneous recombinant human interleukin-12 in patients with advanced renal cell carcinomaR J Motzer, A Rakhit, L H Schwartz, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 11, 2013
Hyperbilirubinemia in pazopanib- or sunitinib-treated patients in COMPARZ is associated with UGT1A1 polymorphismsR J Motzer, T Johnson, T K Choueiri, et al.
British Journal of Cancer|May 10, 2012
Q-TWiST analysis to estimate overall benefit for patients with metastatic renal cell carcinoma treated in a phase III trial of sunitinib vs interferon-αS Patil, R A Figlin, T E Hutson, et al.
Investigational New Drugs|January 1, 1997
A phase II study of 13-cis-retinoic acid in patients with advanced renal cell carcinomaW J Berg, L H Schwartz, A Amsterdam, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 1, 1997
Long-term follow-up of patients with good-risk germ cell tumors treated with etoposide and cisplatinH Xiao, M Mazumdar, D F Bajorin, et al.
Cancer Chemotherapy and Pharmacology|January 1, 1990
Carboplatin-based chemotherapy with pharmacokinetic analysis for patients with hemodialysis-dependent renal insufficiencyR J Motzer, D Niedzwiecki, M Isaacs, et al.
The Journal of Urology|March 1, 1997
Surgery for a post-chemotherapy residual mass in seminomaH W Herr, J Sheinfeld, H S Puc, et al.
Anticancer Research|March 1, 1996
Expression of the retinoblastoma gene product in renal tumorsJ C Presti, V E Reuter, C Cordon-Cardo, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|July 27, 2010
Prognostic factors for progression-free and overall survival with sunitinib targeted therapy and with cytokine as first-line therapy in patients with metastatic renal cell carcinomaS Patil, R A Figlin, T E Hutson, et al.
Pageof 16

Showing results (81-90 of 155) with videos related to

Sort By:
Pageof 16
Investigational New Drugs|February 1, 1993
A phase II trial of deoxyspergualin in recurrent squamous cell head and neck cancerD G Pfister, D Bajorin, R J Motzer, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 2, 1998
Phase I trial of subcutaneous recombinant human interleukin-12 in patients with advanced renal cell carcinomaR J Motzer, A Rakhit, L H Schwartz, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 11, 2013
Hyperbilirubinemia in pazopanib- or sunitinib-treated patients in COMPARZ is associated with UGT1A1 polymorphismsR J Motzer, T Johnson, T K Choueiri, et al.
British Journal of Cancer|May 10, 2012
Q-TWiST analysis to estimate overall benefit for patients with metastatic renal cell carcinoma treated in a phase III trial of sunitinib vs interferon-αS Patil, R A Figlin, T E Hutson, et al.
Investigational New Drugs|January 1, 1997
A phase II study of 13-cis-retinoic acid in patients with advanced renal cell carcinomaW J Berg, L H Schwartz, A Amsterdam, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 1, 1997
Long-term follow-up of patients with good-risk germ cell tumors treated with etoposide and cisplatinH Xiao, M Mazumdar, D F Bajorin, et al.
Cancer Chemotherapy and Pharmacology|January 1, 1990
Carboplatin-based chemotherapy with pharmacokinetic analysis for patients with hemodialysis-dependent renal insufficiencyR J Motzer, D Niedzwiecki, M Isaacs, et al.
The Journal of Urology|March 1, 1997
Surgery for a post-chemotherapy residual mass in seminomaH W Herr, J Sheinfeld, H S Puc, et al.
Anticancer Research|March 1, 1996
Expression of the retinoblastoma gene product in renal tumorsJ C Presti, V E Reuter, C Cordon-Cardo, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|July 27, 2010
Prognostic factors for progression-free and overall survival with sunitinib targeted therapy and with cytokine as first-line therapy in patients with metastatic renal cell carcinomaS Patil, R A Figlin, T E Hutson, et al.
Pageof 16